Daniel P Andersson, K. Littmann, Gustav Kindborg, Daniel Eklund, Kristina Sejersen, Jane Yan, D. E. Hogling, Paolo Parini, J. Brinck
{"title":"Relation between hypertriglyceridemia, cardiometabolic disease and hereditary factors – design and rationale of the Stockholm hyperTRIglyceridemia REGister (STRIREG) study","authors":"Daniel P Andersson, K. Littmann, Gustav Kindborg, Daniel Eklund, Kristina Sejersen, Jane Yan, D. E. Hogling, Paolo Parini, J. Brinck","doi":"10.1093/ehjopen/oeae010","DOIUrl":"https://doi.org/10.1093/ehjopen/oeae010","url":null,"abstract":"\u0000 Hypertriglyceridemia (hTG) is associated with atherosclerotic cardiovascular disease, pancreatitis, and non-alcoholic fatty liver disease in large population-based studies. Less is known about the impact on hereditary hTG and cardiometabolic disease status for the development of hTG and its associated cardiometabolic outcomes. hTG remains a target for lipid lowering therapies and with new pharmacological interventions being developed, there is a need to identify patients that will benefit most from treatment with these new medicines.\u0000 The population-based observational Stockholm hyperTRIglyceridemia REGister (STRIREG) study include 1,460,184 index individuals that have measured plasma triglycerides in the clinical routine in Region Stockholm, Sweden, between 1st January 2000 and 31st December 2021. The laboratory measurements also included basic haematology, blood lipid panel, liver function tests and HbA1c. Using the Swedish Multi-Generation register, 2,147,635 parents and siblings to the indexes were identified to form the complete study cohort. Laboratory data from participants were combined with data from several national registers that provided information on cause of death, medical diagnoses, dispensed medicines, and socioeconomic factors including country of birth, education level and marital status.\u0000 The multigenerational longitudinal STRIREG cohort provides a unique opportunity to investigate different aspects of hTG as well as heredity for other metabolic diseases. Important outcome measures include mortality, cardiovascular mortality, major cardiovascular events, development of incident diabetes, and non-alcoholic fatty liver disease. The STRIREG study will provide a deeper understanding of the impact of hereditary factors and associated cardiometabolic complications.","PeriodicalId":505595,"journal":{"name":"European Heart Journal Open","volume":"15 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139958005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}